Suven Life Sciences share price has zoomed 6% and is presently trading at Rs 121.5.
Meanwhile, the BSE HEALTHCARE index is at 42,783.0 (down 0.7%).
Among the top gainers in the BSE HEALTHCARE index today are ASTRAZENECA PHARMA (up 3.6%) and GSK Pharma (up 1.9%).
IPCA Labs (down 6.0%) and ERIS LIFESCIENCES (down 2.9%) are among the top losers today.
Over the last one year, Suven Life Sciences has moved up from Rs 65.5 to Rs 121.5, registering a gain of Rs 56.0 (up 85.5%).
On the other hand, the BSE HEALTHCARE index has moved up from 27,503.7 to 42,783.0, registering a gain of 55.6% during the last 12 months.
The top gainers among the BSE HEALTHCARE index stocks during this same period were Jubilant Pharmova (up 214.3%), Glenmark Pharma (up 120.3%) and SUVEN PHARMACEUTICALS (up 117.9%).
Don't Miss: Key Information for Long-term Investors
The BSE Sensex is at 79,921.1 (down 0.4%).
The top losers among the BSE Sensex today are JSW Steel (down 1.4%) and Power Grid Corp. (down 1.3%). The most traded stocks in the BSE Sensex are Tata Steel and Tata Motors.
In the meantime, NSE Nifty is at 24,378.2 (down 0.4%). Hindustan Unilever and Shriram Transport are among the top losers in NSE NIFTY.
Over the last 12 months, the BSE Sensex has moved up from 64,571.9 to 79,921.1, registering a gain of 15,349.3 points (up 23.8%).
Suven Life Sciences net profit fell 16.4% YoY to Rs -280 million for the quarter ended June 2024, compared to a loss of Rs 241 million a year ago. Net sales declined 73.5% to Rs 10 million during the period as against Rs 38 million in April-June 2023.
For the year ended March 2024, Suven Life Sciences reported 11.2% increase in net profit to Rs -1,051 million compared to net loss of Rs 1,183 million during FY23. Revenue of the company fell 13.6% to Rs 117 million during FY24.
The current Price to earnings ratio of Suven Life Sciences, based on rolling 12 month earnings, stands at -24.3.
Equitymaster requests your view! Post a comment on "Suven Life Sciences Gains 6%; BSE HEALTHCARE Index Down 0.7%". Click here!
Comments are moderated by Equitymaster, in accordance with the Terms of Use, and may not appear
on this article until they have been reviewed and deemed appropriate for posting.
In the meantime, you may want to share this article with your friends!